ReviewClinical medicine insights. Gastroenterology2018
An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease.
Review in Clinical medicine insights. Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.BMC gastroenterology · 2019Pooled it
- Review
- A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis.Nature communications · 2025Article
- A Novel Mutation in LXRα Uncovers a Role for Cholesterol Sensing in Limiting Metabolic Dysfunction-Associated Steatohepatitis (MASH).bioRxiv : the preprint server for biology · 2024Article
- Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.American heart journal plus : cardiology research and practice · 2024Review
- Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease.Journal of cardiovascular development and disease · 2022Review
- PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool.iScience · 2022Article
- Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD.BMJ open gastroenterology · 2022Article
- Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease.Biomedicines · 2021Review
- Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Review
- Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis.International journal of molecular sciences · 2021Article
- Liver X receptors and liver physiology.Biochimica et biophysica acta. Molecular basis of disease · 2021Review
- It's all about the spaces between cells: role of extracellular matrix in liver fibrosis.Annals of translational medicine · 2021Review
- Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2021Review
- Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.Translational gastroenterology and hepatology · 2021Review
- The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins.International journal of molecular sciences · 2020Review
- A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.Microorganisms · 2020Review
- Phenotypic and Genetic Characterization of Lower LDL Cholesterol and Increased Type 2 Diabetes Risk in the UK Biobank.Diabetes · 2020Article
- Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease.Gastroenterology research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is a common complication in patients with metabolic syndrome. The role of statin therapy specifically for the treatment of NAFLD remains unknown. The aim of this review is to discuss outcomes of recent articles analyzing statin therapy in patients with NAFLD.
findingsA total of 12 trials met the inclusion criteria. Statins were not found to increase the prevalence of NAFLD once confounding variables were considered. Statins were also found to be beneficial in treating dyslipidemia and improving liver function. Histological liver outcomes in patients with NAFLD were controversial. One trial found a reduction in the incidence of hepatocellular carcinoma associated with the use of statins.
conclusionsOverall, therapy with statins appears to be safe for use in patients with NAFLD. Several trials have validated the use of statins for the treatment of dyslipidemia; however, it remains unknown as to whether statins should be used to specifically treat NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.